-
Aptose Biosciences | Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
NASDAQ: APTO Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose’s ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9,…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 29 – NOVEMBER 4, 2023
October 28, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 11/02/2023 ARDX 22.5 27,193 $3.49 Conference 11/02/2023 ELDN 44.2 278 $1.59 Conference 11/03/2023 ACET 36.3 90 $1.26 Conference 11/03/2023 AUPH 23.5 11,055 $7.19 FDA Event 11/04/2023 CRBP 94.6 6,911 $5.21 WEEK: 10/29/2023 – 11/04/2023
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 22-28, 2023
October 20, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE FDA Event 10/22/2023 REGN 3.0 600 $808.47 Conference 10/22/2023 RVMD 37.7 33,800 $27.97 Conference 10/23/2023 HARP 52.4 307 $6.88 FDA Event 10/26/2023 CPRX 13.9 2,074 $12.80 WEEK: 10/22/2023 – 10/28/2023
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…